LONDON (Alliance News) - Immunodiagnostic Systems Holdings PLC on Thursday said it has launched a new assay in its hypertension portfolio, which will measure a patient's levels of adrenocorticotropic hormone.
The specialist producer of manual and automated diagnostic testing kits and instruments said the IDS-iSYS ACTH will become a "key assay" within its portfolio for endocrine hypertension testing.
Together with other clinical and laboratory data, the hormone data obtained from the new assay will allow the differential diagnosis of both hyper-cortisolism and hypo-cortisolism disorders such as Cushing's syndrome and Addison's disease, as well as evaluate potential other causes of the endocrine hypertension.
Shares in Immunodiagnostic were up 1.2% at 253.00 pence on Thursday afternoon.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2017 Alliance News Limited. All Rights Reserved.
